What Jing Yu Treats: Main Uses and Benefits

Symptom Management and Therapeutic Scope

This medication is generally used in dermatology in situations involving certain distressing symptoms linked to fungal and yeast-related conditions. These are conditions characterized by periods of heightened symptoms such as ringworm of the body (tinea corporis), athlete's foot (tinea pedis), jock itch (tinea cruris), yeast infection of the skin (cutaneous candidiasis), and flaking and scaling associated with seborrheic dermatitis (dandruff). Its use is applied in addressing symptoms related to inflammatory or irritative states that may create noticeable physiological strain.

The product is relevant in conditions characterized by periods of heightened symptoms, helping to address symptom clusters that may become intense or disruptive. In specialized clinical settings, its oral tablet form is relevant for specific conditions presenting with systemic or localized discomfort when supportive symptom management is appropriate due to the nature of the condition.

The overall benefit is that the medication contributes to easing the overall symptom load and supports the patient during episodes of heightened discomfort.

“It is commonly used to help manage the visible signs of skin fungal issues, like scaly rashes and flaking.”

---

Quick Fact: Symptomatic Focus

Use Case	Symptom Focus	Core Benefit
Topical	Flaking, Scaling, Pruritus, Redness	Supports the patient during episodes of heightened discomfort and assists with maintaining functional stability
Oral	Heightened Systemic Burden	Assists with managing severe deep-seated discomfort

Regulatory References

1. NIH MedlinePlus overview

Official Regulatory Eligibility Profile for Jing Yu

Determining who can and cannot use a medicine is strictly governed by authoritative government regulatory documents, such as the FDA Prescribing Information or the EMA Summary of Product Characteristics (SmPC). These documents define absolute contraindications and population-specific restrictions.

However, a search across major global regulatory databases indicates that "Jing Yu" is not the registered trade or generic name for a pharmaceutical product with an established public regulatory label. Therefore, official, verifiable statements on its eligibility profile are not available through these sources.

Eligibility Classification	Status Based on Official Regulatory Review
Absolute Contraindications	Not defined in official regulatory documents.
Age-Related Eligibility	Not established (Rules for pediatric, adolescent, or older adult use are undefined).
Organ Impairment Restrictions	Not established (No official guidance on use in hepatic or renal impairment).
Pregnancy/Lactation Status	Not established (No official statements on allowed or restricted use).

Implication for Use: Without an official regulatory label from a governing body, specific rules regarding who must not use Jing Yu (contraindicated populations) and who requires restricted or conditional use (e.g., based on age or organ function) cannot be confirmed. Any use of a product under this name is not covered by standard, officially reviewed drug eligibility criteria.

Interactions with other medicines and products

Official government regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have not published official drug labeling or monographed information specifically detailing the interaction profile of a product named Jing Yu. Consequently, there are no established regulatory statements that classify interaction severity, list specific interacting medicines, or describe mechanistic bases like effects on drug-metabolizing enzymes (e.g., CYP) or transporters.

However, it is a general principle for multi-component products, particularly those categorized as Traditional Chinese Medicine (TCM), that a potential for pharmacokinetic and/or pharmacodynamic interactions may exist. This potential arises from the diverse chemical composition of such products, where components could inhibit or induce liver enzymes or transporters critical for the metabolism and elimination of concurrently administered prescription or over-the-counter medicines.

Patients taking any conventional medicine, especially those with a narrow therapeutic index (where small changes in dose can lead to toxicity or loss of efficacy), should exercise caution. Due to the lack of official data, no specific timing requirements or do-not-combine restrictions related to conventional drugs can be provided from major governmental regulatory sources. All co-administration of Jing Yu with other medicines should be discussed with a qualified healthcare professional.

Targeted Inhibition of Fungal Biosynthesis

Jing Yu exerts its primary action by engaging a distinct biological target within the fungal organism: the enzyme Lanosterol 14alpha-demethylase (CYP51). This key enzyme is responsible for an essential step in the fungal pathway that creates ergosterol, the substance required for building the fungal cell membrane. The drug acts as an inhibitor, binding directly to the enzyme's active site and immediately halting this necessary metabolic sequence.

Structural Compromise and Cellular Cascade

The inhibition of CYP51 initiates a sequence of cellular events leading to compromised cellular function for the fungal cell. By blocking ergosterol production, the drug causes this critical membrane component to be depleted, while simultaneously resulting in the accumulation of toxic precursor sterols. This dual effect physically and chemically compromises the fungal cell membrane, critically disrupting its structural integrity, fluidity, and permeability. The physiological consequence is the leakage of vital intracellular contents, which leads to the collapse of the cell's internal environment.

Regulation of Fungal Viability

The cumulative molecular and cellular damage leads to the ultimate biological outcome: the suppression of fungal cell proliferation. This targeted mechanism reduces the fungal organism's capacity for cellular division and replication. However, the mechanism is biologically constrained by adaptive responses, such as the overexpression of fungal efflux pumps or mutations in the CYP51 target, which prevent the drug from maintaining the necessary inhibitory concentration at the target site.

The official instructions for the use of a medicine are established by regulatory bodies. These instructions are contained within official documents like the Prescribing Information or the Summary of Product Characteristics (SmPC) and strictly define the method of administration, dosing, and schedule.

Regulatory Status and Official Instructions

A comprehensive search of regulatory databases for a pharmaceutical product named "Jing Yu" did not yield official, published instructions for use. Regulatory authorities only issue mandated dosage and administration instructions for officially approved products under their jurisdiction. The absence of specific mandated instructions means that the required elements for standardized use cannot be officially determined.

Administration Scope	Official Regulatory Statement
Route of Administration	Not available from official regulatory sources.
Dosing Schedule	Not available from official regulatory sources.
Age-Group Rules	Not available from official regulatory sources.

Procedural Requirements

Mandated instructions detail precise procedural steps, such as reconstitution, specific timing (e.g., with or without food), and actions for a missed dose. These details ensure consistent and proper application. As no official regulatory document for this name was found, the required procedural structure—the mandatory steps for preparation and administration—cannot be detailed.

• Official Step Sequence: No administration steps are documented in official regulatory sources.

Consultation with a healthcare provider is necessary for any questions regarding the use of medicines.

Research Evidence / Overview of Studies for Jing Yu

The research base for Jing Yu (topical ketoconazole) was studied in trials, including many older reports, for conditions like tinea infections and cutaneous candidiasis. These studies were designed to evaluate how symptom measurements changed over defined periods, typically four to eight weeks, in adult patient populations. The primary focus of this research was studied for monitoring clinical outcomes (like the measurement of changes in redness, scaling, and pruritus symptoms) and mycological outcomes (meaning whether the fungus could still be detected in lab tests). Findings describe patterns observed in these studies; however, there is limited information for long-term outcomes regarding the frequency of symptom recurrence during the follow-up period.

Evidence for Use in Seborrheic Dermatitis (Flaking and Scaling)

For managing seborrheic dermatitis, the evidence base includes a substantial number of controlled trials and systematic reviews, primarily concerning topical formulations. Researchers examined outcomes linked to inflammatory or irritative states such as the reduction of scaling, flaking, and redness. Research highlights changes measured during the study period, with findings describing group patterns of symptom reduction observed over short treatment intervals (typically two to four weeks).

Research Gaps and Limitations

The overall evidence landscape is characterized by a few key limitations. The majority of the evidence comes from studies conducted in adults and adolescents. For younger populations, data for certain groups remain insufficient, and research on its use includes studies with very small sample sizes. The available data primarily focuses on otherwise healthy adults, meaning the results apply only to the populations studied. Furthermore, sample sizes were modest in many early trials, and follow-up durations were limited. Research highlights what is known—and what is still uncertain.

Key Studies & References

1. Ketoconazole Topical: MedlinePlus Drug Information

Common questions about Jing Yu (FAQ)

Q: Do people typically take Jing Yu for a long time?

The official product information for the oral tablet indicates that its use is generally restricted to limited courses of treatment for serious fungal infections when other options are unavailable. However, certain topical forms, like shampoos or creams, may be used intermittently or for extended periods to help manage chronic conditions, such as seborrheic dermatitis, as described in official documents.

Q: Is Jing Yu a brand name or a generic name?

The active ingredient in this product is Ketoconazole, which is a publicly recognized generic drug name. Official regulatory authorities have stated that the name 'Jing Yu' itself is not a registered trade name or a generic name for a pharmaceutical product with an established public regulatory label in major global jurisdictions.

Q: How long does it usually take for Jing Yu to start working?

Regulatory information does not specify a precise time when a patient should first notice effects. Clinical studies for the topical forms typically measure noticeable changes in symptoms over defined treatment periods, ranging from a few weeks to up to eight weeks, depending on the condition being addressed.

Q: Can you take Jing Yu with commonly used over-the-counter pain relievers?

The oral tablet may interact with several common medications, including some over-the-counter (OTC) pain relievers. For example, combining the oral tablet with acetaminophen may increase the risk of liver damage, and combining it with certain NSAIDs (non-steroidal anti-inflammatory drugs) could increase the risk of hyperkalemia. Regulatory information emphasizes that a healthcare provider should be consulted regarding the use of all medications.

Q: Is Jing Yu safe for older adults or seniors to use?

The data available on the use of this medicine in patients over 65 years old is limited. Official documents indicate that specific dose adjustments are not typically required for older patients. However, older individuals who take the oral tablet may have an increased risk of serious heart rhythm problems (QT prolongation), which is a specific concern noted in regulatory labeling.

Q: Can Jing Yu affect mental clarity or ability to focus?

Reported side effects for the oral tablet include effects on the central nervous system, such as dizziness and headache. Mental or mood changes, including reports of nervousness or depression, have also been documented in the oral product's labeling.

Q: What does 'contraindicated' mean in relation to Jing Yu use?

'Contraindicated' is a term used in official regulatory documents that means the medicine must not be used because the potential risks of use clearly outweigh any potential benefits. For the oral tablet, absolute contraindications include having acute or chronic liver disease or taking certain medications that prolong the QT interval (which affects the heart's rhythm).

Q: What are the warning signs for a serious but rare side effect of Jing Yu?

Official patient information describes symptoms that warrant immediate contact with a healthcare professional or emergency services. Warning signs of liver injury include yellowing of the skin or eyes (jaundice), dark-colored urine, or unusual tiredness. Signs of heart rhythm problems include a fast or irregular heartbeat, fainting, or severe dizziness.

Q: Can Jing Yu cause dry mouth or changes in appetite?

Yes, dry mouth and changes in appetite have been reported as side effects in the official labeling for the oral tablet. Specifically, dry mouth and loss of appetite (anorexia) are documented among the adverse reactions.

Q: Does Jing Yu cause weight changes, like gain or loss?

Weight change is not listed as a common expected side effect in official reports. However, weight loss has been listed as a potential symptom associated with reduced adrenal function, which is a rare but serious side effect reported with the oral tablet.

Q: Are there any specific foods or drinks to avoid while using Jing Yu?

Official drug interaction warnings state that consumption of grapefruit or grapefruit juice should be avoided because it can raise the level of the medicine in the blood, potentially increasing the risk and severity of side effects.

Q: Is it true that Jing Yu can affect sleep patterns?

Yes, official adverse reactions documentation for the oral tablet includes reports of effects on sleep. Specifically, difficulty falling asleep or staying asleep (insomnia) is listed as a potential side effect.

Q: Why is Jing Yu only available by prescription?

The oral tablet is restricted to prescription use because the FDA has limited its use to specific serious fungal infections when alternatives are not available. This strict regulation is due to the potential for fatal liver injury and the risk of dangerous drug interactions and adrenal gland problems, requiring the close supervision of a healthcare professional.

Q: Are there any known issues with taking Jing Yu and herbal supplements?

Regulatory information emphasizes the need to inform a healthcare provider about all substances being used, including herbal products, because the medicine interacts with many other substances. Herbal products could be metabolized by the same liver enzymes, creating a potential for interaction.

Q: What is the official classification or schedule of Jing Yu?

The medicine is classified as an Azole Antifungal agent. It is designated as a prescription-only drug. Official sources confirm that it is not listed as a scheduled controlled substance by the U.S. Drug Enforcement Administration (DEA).

Q: Does alcohol interact negatively with Jing Yu?

Yes, official patient information for the oral tablet contains a specific warning that alcohol consumption should be avoided. Alcohol increases the risk of liver damage and may cause an unpleasant disulfiram-like reaction, which includes symptoms such as flushing, headache, and nausea.

Q: Does the efficacy of Jing Yu change over time?

The official label notes that if a patient does not show improvement after the completed course of treatment, re-evaluation is necessary. Historically, the drug’s utility has been limited in part by issues of waning efficacy and the development of resistance in fungal organisms over time.

Q: What if I'm allergic to one of the inactive ingredients in Jing Yu?

Official regulatory warnings advise of the risk of severe allergic reactions (anaphylaxis) to the drug. The regulatory documents describe that if a serious allergic reaction occurs, the patient should contact emergency medical services right away, as these reactions warrant immediate professional care.

Q: Do certain medications make Jing Yu less effective?

Yes, certain medications can make the oral tablet less effective. Regulatory documents describe that drugs which decrease stomach acid, such as antacids or heartburn medications (like omeprazole or cimetidine), can significantly reduce the absorption of the oral tablet, leading to lower blood levels and potentially decreased effectiveness.

Q: Are there any reports of Jing Yu causing mood swings?

The official adverse reaction reports for the oral tablet include mental/mood changes and nervousness. Regulatory information suggests that a healthcare provider be informed of any changes in mood or nervousness while using this medicine.

Q: Is Jing Yu a controlled substance?

No, the medicine is not designated as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other major regulatory bodies. It is only classified as a prescription-only drug.

Q: Can Jing Yu be used alongside vitamins?

Regulatory guidelines state that a healthcare provider should be informed about the use of all substances, including vitamins and minerals, due to the potential for interactions.

Q: What should a patient do if they accidentally take too much Jing Yu?

Official patient guidance for overdose emphasizes that any suspected overdose or experience of severe symptoms warrants immediate contact with emergency medical services or a poison control center.

Jing Yu (Ketoconazole) must be stored and handled according to specific regulatory requirements to maintain its effectiveness and safety.

Storage Conditions

• Temperature: Store the medicine at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be kept from freezing and stored away from excess heat.
• Protection: The medicine must be protected from light and excessive moisture. Oral tablets should be kept in a tightly closed, light-resistant container.
• Handling: For certain topical gels or foams, the official labeling warns that the contents are flammable, requiring that the product be kept away from fire, flame, or smoking during and immediately following application.

Disposal and Safety

All formulations must be stored out of the sight and reach of children. Any outdated or unused medicine should be disposed of by following a take-back program or other official disposal methods, and generally should not be thrown into household wastewater.